Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial

British Journal of Nutrition

Volumn 117, Issue 5, 2017, Pages 662-668

  Mofidi, Fatemeh ^a   Poustchi, Hossein ^b   Yari, Zahra ^a   Nourinayyer, Babak ^c   Merat, Shahin ^b   Sharafkhah, Maryam ^b,d   Malekzadeh, Reza ^e   Hekmatdoost, Azita ^a,f  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Mehrad General Hospital   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Body weight; Fatty liver; Non alcoholic fatty liver diseases; Non alcoholic steatohepatitis; Prebiotics; Probiotics; Synbiotics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; PLACEBO; SYNBIOTIC AGENT; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; GLUCOSE BLOOD LEVEL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELASTOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS RHAMNOSUS; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; BLOOD; DIETARY SUPPLEMENT; INFLAMMATION; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLACEBOS; SYNBIOTICS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 85016232480     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114517000204     Document Type: Article

References (35)

1. Hashimoto E, Taniai M & Tokushige K (2013) Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol 28, Suppl. 4, 64-70.
2. Ghaemi A, Taleban FA, Hekmatdoost A, et al. (2013) How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon 13, e15227.
3. Vos B, Moreno C, Nagy N, et al. (2011) Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 74, 389-394.
4. Eckburg PB, Bik EM, Bernstein CN, et al. (2005) Diversity of the human intestinal microbial flora. Science 308, 1635-1638.
5. Fanaro S, Chierici R, Guerrini P, et al. (2003) Intestinal microflora in early infancy: composition and development. Acta Paediatr Suppl 92, 48-55.
6. Mahowald MA, Rey FE, Seedorf H, et al. (2009) Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci U S A 106, 5859-5864.
7. McCarthy J, O'mahony L, O'callaghan L, et al. (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52, 975-980.
8. Lim CC, Ferguson LR & Tannock GW (2005) Dietary fibres as 'prebiotics': implications for colorectal cancer. Mol Nutr Food Res 49, 609-619.
9. Saulnier DM, Gibson GR & Kolida S (2008) In vitro effects of selected synbiotics on the human faecal microbiota composition. FEMS Microbiol Ecol 66, 516-527.
10. Eslamparast T, Poustchi H, Zamani F, et al. (2014) Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99, 535-542.
11. Velayudham A, Dolganiuc A, Ellis M, et al. (2009) VSL# 3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet?induced nonalcoholic steatohepatitis model in mice. Hepatology 49, 989-997.
12. Mofidi F, Yari Z, Poustchi H, Merat S, et al. (2016) Effects of synbiotics supplementation in lean patients with nonalcoholic fatty liver disease: study protocol of a pilot randomized double-blind clinical trial. Arch Iran Med 19, 282-284.
13. National Heart, Lung, and Blood Institute Obesity Education Initiative, National Heart, Lung, and Blood Institute & North American Association for the Study of Obesity (2002) The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. San Antonio, TX: National Heart, Lung, and Blood Institute.
14. Fabbrini E, Sullivan S & Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679-689.
15. Vernon G, Baranova A & Younossi Z (2011) Systematic review: the epidemiology and natural history of non?alcoholic fatty liver disease and non?alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34, 274-285.
16. Nakatsuka A, Matsuyama M, Yamaguchi S, et al. (2016) Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis. Sci Rep 6, 21721.
17. Margariti E, Deutsch M, Manolakopoulos S, et al. (2012) Nonalcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol 25, 45-51.
18. Strieter R, Chensue S, Basha M, et al. (1990) Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-alpha, lipopolysaccharide, and interleukin-1 beta. Am J Respir Cell Mol Biol 2, 321-326.
19. Iacono A, Raso GM, Canani RB, et al. (2011) Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 22, 699-711.
20. Aller R, De Luis DA, Izaola O, et al. (2011) Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15, 1090-1095.
21. Malaguarnera M, Vacante M, Antic T, et al. (2012) Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57, 545-553.
22. Li Z, Yang S, Lin H, et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343-350.
23. Eslamparast T, Zamani F, Hekmatdoost A, et al. (2014) Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, doubleblind, placebo-controlled pilot study. Br J Nutr 112, 438-445.
24. Yadav H, Jain S & Sinha PR (2007) Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 23, 62-68.
25. Ma X, Hua J & Li Z (2008) Probiotics improve high fat dietinduced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49, 821-830.
26. Compare D, Coccoli P, Rocco A, et al. (2012) Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 22, 471-476.
27. Hosseini E, Grootaert C, Verstraete W, et al. (2011) Propionate as a health-promoting microbial metabolite in the human gut. Nutr Rev 69, 245-258.
28. Hamer HM, Jonkers D, Venema K, et al. (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104-119.
29. van der Beek CM, Canfora EE, Lenaerta K, et al. (2016) Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. Clin Sci (Lond) 130, 2073-2082.
30. Zhu L, Baker RD & Baker SS (2015) Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res 77, 245-251.
31. Abenavoli L & Beaugrand M (2012)) Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol 11, 172-178.
32. Malekzadeh R & Poustchi H (2011) Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon 11, 157.
33. Angulo P, Hui JM, Marchesini G, et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846-854.
34. Lindor KD, Kowdley KV, Heathcote EJ, et al. (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39, 770-778.
35. Loguercio C, Federico A, Tuccillo C, et al. (2005) Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39, 540-543.